You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. CATALYST PHARMACEUTICALS INC

Catalyst Pharmaceuticals Inc XNAS: CPRX

Catalyst Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

Mid-range Performer
Download real time

23.07 -1.04 (-4.31%)

59.43% Gain from 52W Low

2.2M XNAS Volume

XNAS 04 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Catalyst Pharmaceuticals Inc Key Metrics

Default

Market Capitalization

High in industry
2,801.8

PE TTM

High in industry
17.1

PEG TTM

Below industry Median
0.1

Price to Book

Below industry Median
3.9

Institutional holding current Qtr %

Below industry Median
80.4

Revenue Growth Qtr YoY %

Below industry Median
28.3

Operating Revenue growth TTM %

Below industry Median
23.5

Net Profit Qtr Growth YoY %

Below industry Median
60.5

Net Profit TTM Growth %

High in industry
129.5

Operating Profit Margin Qtr %

High in industry
44.3

Operating Profit Margin TTM %

High in industry
39.7

Piotroski Score

High in industry
7

Rel Perf vs Sector quarter%

10.6

ROE Annual %

High in industry
29.4

RoA Annual %

High in industry
24.8
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
High Financial Strength
72.2 / 100
Valuation Score
Mid Valuation
41.2 / 100
Momentum Score
Technically Neutral
59.3 / 100
Mid-range Performer These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest. View Similar Embed DVM
Analyst Price Target
34
1Yr Price target upside is 47%
8 analysts

21

S

6

W

1

O

2

T

SWOT Analysis

Catalyst Pharmaceuticals Inc Live Price Chart

Switch to TradingView
Created with Highcharts 9.0.1Chart context menu29. Apr27. May24. Jun22. Jul19. Aug16. Sep14. Oct11. Nov9. Dec6. Jan3. Feb3. Mar31. Mar200820102012201420162018202020222024201015253008MZoom1D1W1M3M1Y5YAllApr 4, 2024→Apr 4, 2025trendlyne.com

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '260250500750Actual RevenueAvg. Estimate
Hit

Catalyst Pharmaceuticals Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

Current EPS
1.3
Avg. Estimate
1.4
Low Estimate
1.3
High Estimate
1.8
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 9.2% in FY25

Consensus Recommendation

8 ANALYST Recommendations
STRONG BUY

Created with Highcharts 7.2.21Buy7Strong Buy

The consensus recommendation from 8 analysts for Catalyst Pharmaceuticals Inc is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Catalyst Pharmaceuticals Inc Stock Analysis

Catalyst Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Catalyst Pharmaceuticals Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$491.73 M23.49%positive

Annual Revenue rose 23.49%, in the last year to $491.73 M. Its sector's average revenue growth for the last fiscal year was 7.48%.

Annual Net Profit$163.89 M129.5%positive

Annual Net Profit rose 129.5% in the last year to $163.89 M. Its sector's average net profit growth for the last fiscal year was -32.26%.

Price to Earning Ratio17.1-negative

Price to Earning Ratio is 17.1, higher than its sector PE ratio of 3.57.

Stock Price$23.0752.58%positive

Stock Price rose 52.58% and outperformed its sector by 53.3% in the past year.

Quarterly Revenue$141.82 M28.26%positive

Quarterly Revenue rose 28.26% YoY to $141.82 M. Its sector's average revenue growth YoY for the quarter was 5.95%.

Quarterly Net profit$55.94 M60.53%positive

Quarterly Net profit rose 60.53% YoY to $55.94 M. Its sector's average net profit growth YoY for the quarter was -47.42%.

Debt to Equity Ratio--positive

Debt to Equity Ratio is zero as the company is debt-free.

Return on Equity(ROE)29.38 %29.38%positive

Return on Equity(ROE) for the last financial year was 29.38%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

Mutual Fund Holding58.35 %-3.66%negative

Mutual Fund Holding decreased by 3.66% in the last quarter to 58.35.

Promoter Share Holding7.37 %0.11%positive

Promoter Share Holding increased by 0.11% in the most recent quarter to 7.37%.

Institutional Holding80.43 %0%neutral

Institutional Holding remained the same in the last quarter at 80.43%.

VIEW LESS


Loading data..

Catalyst Pharmaceuticals Inc - Company Profile

What does Catalyst Pharmaceuticals Inc do?

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Catalyst Pharmaceuticals Inc Management structure

All Gross Remunerations are in USD
Mr. Michael W. Kalb
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Richard J. Daly
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year

Catalyst Pharmaceuticals Inc Board of directors

All Gross Remunerations are in USD
Mr. Charles B. O'Keeffe
Lead Independent Director
-
2025
Gross Remuneration
Year

Catalyst Pharmaceuticals Inc FAQ

How is Catalyst Pharmaceuticals Inc today?
Catalyst Pharmaceuticals Inc today is trading in the red, and is down by -4.31% at 23.07.
Catalyst Pharmaceuticals Inc is currently trading down -4.31% on an intraday basis. In the past week the stock fell -6.56%. stock has been up 7.45% in the past quarter and rose 52.58% in the past year. You can view this in the overview section.